(Q47774205)

English

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

4

object named as

Maximilian von Eynatten

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

author name string

Anthony H Barnett

1

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Holger Huisman

2

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Russell Jones

3

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Sanjay Patel

5

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Hans-Juergen Woerle

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

language of work or name

0 references

publication date

13 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

382

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

9902

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

1413-1423

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Are current clinical trials in diabetes addressing important issues in diabetes care?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes and cognitive impairment: linking mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Special considerations for treatment of type 2 diabetes mellitus in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of patients with sulphonurea-induced hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961500-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)61500-7

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/23948125

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47774205&oldid=2170507858"